situations

L-Alanyl-L-glutamine (Ala-Gln) 是一种由丙氨酸和谷氨酰胺组成的二肽，对抗氧化系统有益，能够减轻炎症，并能够在分解代谢情况下调节热休克蛋白 (HSP) 的反应。

Labetalol (Apo-Labetalol) 是一种抗高血压药物，可用于心血管疾病的研究，如妊娠期高血压。它是一种口服具有活性的选择性 α1- 和非选择性 β-肾上腺素能受体 (adrenergic receptor) 竞争性拮抗剂。

VU 0255035 是高度选择性、竞争性和血脑屏障通透性的毒蕈碱 M1 受体拮抗剂，IC50为 130 nM，可减少毛果芸香碱诱导的小鼠癫痫发作。

FR-168888, a new Na+ H+ exchange inhibitor, can protect the heart from arrhythmia and myocardial cell death in ischemic and reperfused situations.

Latanoprost is an F-series prostaglandin (PG) analog which has been approved for use as an ocular hypotensive drug. Oxidation of the C-15 hydroxyl group without isopropyl ester hydrolysis produces 15-keto latanoprost. 15-keto Latanoprost is a potential metabolite of latanoprost when administered to animals. 15-keto Latanoprost is also one of the common minor impurities found in commercial preparations of the bulk drug compound. Although much less potent that the parent compound latanoprost, 15-keto latanoprost still retains the ability to produce a small but measurable decrease (1 mm Hg) in the intraocular pressure of normal cynomolgus monkeys when administered at a dose of 1 μg/eye. 15-keto Latanoprost is also a miotic in the normal cat eye, causing an 8 mm reduction in pupillary diameter at 5 μg/eye. Again, this is not as potent as many other F-type PGs; for example, PGF2α will produce this degree of miosis at a dose of less than 1 μg/eye. Products of β-oxidation account for most of the metabolites of latanoprost recovered in plasma and urine. However, 15-keto latanoprost is a minor metabolite, and one which could be enhanced in situations where β-oxidation is reduced.

FR-168888 free base is a new Na+ H+ exchange inhibitor. FR-168888 has a strong inhibitory effect on Na+ H+ exchange and has been shown to protect the heart from arrhythmia and myocardial cell death in ischemic and reperfused situations.

ZD7114, also known as ICI-D7114, is a selective adrenoceptor agonist of brown fat and thermogenesis. ICI D7114 stimulates thermogenesis at doses that have little effect on beta 1 or beta 2 adrenoceptors. Treatment with ICI D7114 activates BAT and thermogenesis even in species and situations where the intrinsic capacity is low. ICI D7114 has beneficial effects in animal models of obesity and disturbed glucose and lipid homeostasis.

MyoMed-205 是一种MuRF1(肌肉环指蛋白1) 活性抑制剂。它可以防止单侧膈神经去神经12小时后引起的早期膈肌收缩功能障碍和萎缩。通过抑制MuRF1活性，MyoMed-205 减少了肌肉蛋白的泛素化和后续的蛋白酶体降解。此外，MyoMed-205 能提高磷酸化Akt(ser473)的蛋白水平，Akt对肌肉的生长和维持至关重要。MyoMed-205 适用于研究和治疗由早期失用引起的膈肌功能障碍和萎缩(DIDD)，尤其是在膈肌麻痹或机械通气等临床情况下。